significantTreatment update
AIDA Network real-world IL-1 inhibitor data: 60-month retention 64.7%
Schnitzler Syndrome →Summary
Calabrese et al. (2025) reported long-term real-world effectiveness of anakinra and canakinumab in 28 SchS patients (37 treatment lines) from the international AIDA Network registry. Complete response rates were 73.1% (anakinra) and 66.8% (canakinumab). Drug retention at 60 months was 64.7%. Elevated IgG M-protein and lymphadenopathy independently predicted treatment discontinuation.
Related treatments
Source
Grade Bcohort
IL-1 targeting agents in Schnitzler syndrome: a multicentre, real-world study from the international AIDA Network
Calabrese L, Cartocci A, et al. · Clin Exp Rheumatol · 2025
- •Multicentre real-world data on IL-1 blockers in Schnitzler syndrome from AIDA network
More from Schnitzler Syndrome
incrementalNew research
Weekly research monitor: 4 new sources added (2025-2026)
significantNew research
Neutrophils identified as predominant IL-1β source in SchS skin
incrementalGenetic finding
Low-level NLRP3 mosaicism extends Schnitzler phenotypic spectrum
incrementalNew research
Weekly research monitor: 7 new sources added (2025-2026)
ID: schnitzler-syndrome-update-5Type: treatment_updateImpact: significant